SE446406B - Nya foreningar med karcinostatisk och immunostimulerande verkan framstellda genom odling av fusobacterium nucleatum tf-031(ferm 5077, atcc 31647), forfarande for framstellning av desamma och karcinostatiskt medel inneha - Google Patents
Nya foreningar med karcinostatisk och immunostimulerande verkan framstellda genom odling av fusobacterium nucleatum tf-031(ferm 5077, atcc 31647), forfarande for framstellning av desamma och karcinostatiskt medel innehaInfo
- Publication number
- SE446406B SE446406B SE8005921A SE8005921A SE446406B SE 446406 B SE446406 B SE 446406B SE 8005921 A SE8005921 A SE 8005921A SE 8005921 A SE8005921 A SE 8005921A SE 446406 B SE446406 B SE 446406B
- Authority
- SE
- Sweden
- Prior art keywords
- phosphate buffer
- sulfuric acid
- reaction
- sodium chloride
- fraction
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 139
- 230000003327 cancerostatic effect Effects 0.000 title claims description 48
- 230000003308 immunostimulating effect Effects 0.000 title claims description 20
- 241000605986 Fusobacterium nucleatum Species 0.000 title claims description 10
- 150000001875 compounds Chemical class 0.000 title description 2
- 238000004519 manufacturing process Methods 0.000 title description 2
- 239000008363 phosphate buffer Substances 0.000 claims description 179
- 239000000126 substance Substances 0.000 claims description 168
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 144
- 239000000243 solution Substances 0.000 claims description 127
- IBUIVNCCBFLEJL-UHFFFAOYSA-M sodium;phosphoric acid;chloride Chemical compound [Na+].[Cl-].OP(O)(O)=O IBUIVNCCBFLEJL-UHFFFAOYSA-M 0.000 claims description 86
- 238000006243 chemical reaction Methods 0.000 claims description 84
- 238000010521 absorption reaction Methods 0.000 claims description 74
- 239000011780 sodium chloride Substances 0.000 claims description 72
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 69
- 239000000843 powder Substances 0.000 claims description 53
- 150000002500 ions Chemical class 0.000 claims description 51
- 229920005654 Sephadex Polymers 0.000 claims description 50
- 239000012507 Sephadex™ Substances 0.000 claims description 50
- 238000000862 absorption spectrum Methods 0.000 claims description 49
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 48
- 239000002244 precipitate Substances 0.000 claims description 47
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 45
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 44
- 238000000108 ultra-filtration Methods 0.000 claims description 43
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 42
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 42
- 238000010828 elution Methods 0.000 claims description 40
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 39
- 238000000502 dialysis Methods 0.000 claims description 34
- 239000007788 liquid Substances 0.000 claims description 33
- 241000699670 Mus sp. Species 0.000 claims description 30
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 28
- 230000008569 process Effects 0.000 claims description 28
- 239000003480 eluent Substances 0.000 claims description 27
- 239000010200 folin Substances 0.000 claims description 26
- 206010028980 Neoplasm Diseases 0.000 claims description 24
- 238000002523 gelfiltration Methods 0.000 claims description 24
- 239000008103 glucose Substances 0.000 claims description 21
- 239000001963 growth medium Substances 0.000 claims description 21
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 20
- 208000003468 Ehrlich Tumor Carcinoma Diseases 0.000 claims description 18
- 239000007864 aqueous solution Substances 0.000 claims description 17
- 244000309466 calf Species 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 claims description 16
- 150000001720 carbohydrates Chemical class 0.000 claims description 15
- 239000006228 supernatant Substances 0.000 claims description 15
- 239000001888 Peptone Substances 0.000 claims description 14
- 108010080698 Peptones Proteins 0.000 claims description 14
- 239000000872 buffer Substances 0.000 claims description 14
- 238000000921 elemental analysis Methods 0.000 claims description 14
- 239000000499 gel Substances 0.000 claims description 14
- RJTZUHVCZIGJMB-UHFFFAOYSA-N hydron;1h-indole;chloride Chemical compound Cl.C1=CC=C2NC=CC2=C1 RJTZUHVCZIGJMB-UHFFFAOYSA-N 0.000 claims description 14
- 238000005342 ion exchange Methods 0.000 claims description 14
- 238000002844 melting Methods 0.000 claims description 14
- 230000008018 melting Effects 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- 235000019319 peptone Nutrition 0.000 claims description 14
- 102000007562 Serum Albumin Human genes 0.000 claims description 13
- 108010071390 Serum Albumin Proteins 0.000 claims description 13
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims description 13
- 241000894006 Bacteria Species 0.000 claims description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 12
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 claims description 12
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 12
- 201000009030 Carcinoma Diseases 0.000 claims description 11
- 238000001802 infusion Methods 0.000 claims description 11
- 239000003960 organic solvent Substances 0.000 claims description 11
- 238000012258 culturing Methods 0.000 claims description 9
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 8
- 159000000009 barium salts Chemical class 0.000 claims description 8
- 229920001817 Agar Polymers 0.000 claims description 7
- 239000008272 agar Substances 0.000 claims description 7
- 229910001422 barium ion Inorganic materials 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims description 6
- 239000004158 L-cystine Substances 0.000 claims description 6
- 235000019393 L-cystine Nutrition 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- 229960003067 cystine Drugs 0.000 claims description 6
- 239000012153 distilled water Substances 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 235000010265 sodium sulphite Nutrition 0.000 claims description 6
- 239000012138 yeast extract Substances 0.000 claims description 6
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Diphosphoinositol tetrakisphosphate Chemical compound OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 claims description 5
- 229910052788 barium Inorganic materials 0.000 claims description 5
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims description 5
- 210000004556 brain Anatomy 0.000 claims description 5
- 229940041514 candida albicans extract Drugs 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 230000000747 cardiac effect Effects 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 238000010494 dissociation reaction Methods 0.000 claims description 5
- 230000005593 dissociations Effects 0.000 claims description 5
- WHWDWIHXSPCOKZ-UHFFFAOYSA-N hexahydrofarnesyl acetone Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)=O WHWDWIHXSPCOKZ-UHFFFAOYSA-N 0.000 claims description 5
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 claims description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical group [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims description 4
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 3
- 238000001228 spectrum Methods 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 229940071127 thioglycolate Drugs 0.000 claims description 3
- 108010050327 trypticase-soy broth Proteins 0.000 claims description 3
- 239000003638 chemical reducing agent Substances 0.000 claims description 2
- 229940046307 sodium thioglycolate Drugs 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 238000011481 absorbance measurement Methods 0.000 claims 44
- 239000002904 solvent Substances 0.000 claims 20
- 239000011800 void material Substances 0.000 claims 12
- 208000006268 Sarcoma 180 Diseases 0.000 claims 7
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 5
- 238000005259 measurement Methods 0.000 claims 3
- 238000002835 absorbance Methods 0.000 claims 2
- RXXCIBALSKQCAE-UHFFFAOYSA-N 3-methylbutoxymethylbenzene Chemical compound CC(C)CCOCC1=CC=CC=C1 RXXCIBALSKQCAE-UHFFFAOYSA-N 0.000 claims 1
- FIHZWZBEAXASKA-UHFFFAOYSA-N Anthron Natural products COc1cc2Cc3cc(C)cc(O)c3C(=O)c2c(O)c1C=CC(C)C FIHZWZBEAXASKA-UHFFFAOYSA-N 0.000 claims 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims 1
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 235000021466 carotenoid Nutrition 0.000 claims 1
- 150000001747 carotenoids Chemical class 0.000 claims 1
- 210000003918 fraction a Anatomy 0.000 claims 1
- 229960001031 glucose Drugs 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 229960001375 lactose Drugs 0.000 claims 1
- 229960002668 sodium chloride Drugs 0.000 claims 1
- 229940001482 sodium sulfite Drugs 0.000 claims 1
- 238000001179 sorption measurement Methods 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 238000005406 washing Methods 0.000 description 26
- 238000004108 freeze drying Methods 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 19
- 239000002504 physiological saline solution Substances 0.000 description 16
- 210000004881 tumor cell Anatomy 0.000 description 16
- 239000000203 mixture Substances 0.000 description 14
- 238000001914 filtration Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 238000001990 intravenous administration Methods 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 238000005119 centrifugation Methods 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000002054 transplantation Methods 0.000 description 8
- 101100298295 Drosophila melanogaster flfl gene Proteins 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 241000605909 Fusobacterium Species 0.000 description 6
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 229960004194 lidocaine Drugs 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- 229920000298 Cellophane Polymers 0.000 description 5
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 5
- 229910001863 barium hydroxide Inorganic materials 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 208000001382 Experimental Melanoma Diseases 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012510 hollow fiber Substances 0.000 description 3
- 239000002198 insoluble material Substances 0.000 description 3
- 229940126701 oral medication Drugs 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N D-Maltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical class CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 229940066779 peptones Drugs 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- SYQQWGGBOQFINV-FBWHQHKGSA-N 4-[2-[(2s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-2-yl]ethoxy]-4-oxobutanoic acid Chemical compound C1CC2=CC(=O)[C@H](CCOC(=O)CCC(O)=O)C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 SYQQWGGBOQFINV-FBWHQHKGSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000023514 Barrett esophagus Diseases 0.000 description 1
- 101100038180 Caenorhabditis briggsae rpb-1 gene Proteins 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- 101000651310 Desulfitobacterium hafniense (strain Y51) Trigger factor 2 Proteins 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 1
- 102220543081 Leucine-rich repeat-containing protein 45_C25M_mutation Human genes 0.000 description 1
- 241001446467 Mama Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- MTDMHAKNYZTKQR-UHFFFAOYSA-N [Ba][Ba] Chemical compound [Ba][Ba] MTDMHAKNYZTKQR-UHFFFAOYSA-N 0.000 description 1
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- -1 acetone and the like Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- BJHIKXHVCXFQLS-UYFOZJQFSA-N keto-D-fructose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000002399 phagocytotic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003307 reticuloendothelial effect Effects 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- GNBVPFITFYNRCN-UHFFFAOYSA-M sodium thioglycolate Chemical compound [Na+].[O-]C(=O)CS GNBVPFITFYNRCN-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 125000001874 trioxidanyl group Chemical group [*]OOO[H] 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/04—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Compounds Of Unknown Constitution (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10781879A JPS5630997A (en) | 1979-08-24 | 1979-08-24 | Carcinostatic substance tf-120, its preparation, and carcinostatic comprizing it |
| JP10781479A JPS5630995A (en) | 1979-08-24 | 1979-08-24 | Carcinostatic substance tf-100, its preparation, and carcinostatic comprizing it |
| JP10781979A JPS5645496A (en) | 1979-08-24 | 1979-08-24 | Carcinostatic substance, tf-130, its preparation and carcinostatic preparation containing the same |
| JP10781779A JPS5630996A (en) | 1979-08-24 | 1979-08-24 | Carcinostatic substance tf-110, its preparation, and carcinostatic comprizing it |
| JP10812180A JPS5732294A (en) | 1980-08-06 | 1980-08-06 | Carcinostatic substance tf-133b, its preparation, and carcinostatic agent containing the same |
| JP10812480A JPS5732297A (en) | 1980-08-06 | 1980-08-06 | Carcinostatic substance tf-150, its preparation, and carcinostatic agent containing the same |
| JP10812080A JPS5732293A (en) | 1980-08-06 | 1980-08-06 | Carcinostatic substance tf-132b, its preparation, and carcinostatic agent containing the same |
| JP10812380A JPS5732296A (en) | 1980-08-06 | 1980-08-06 | Carcinostatic substance tf-140, its preparation, and carcinostatic agent containing the same |
| JP10812280A JPS5732295A (en) | 1980-08-06 | 1980-08-06 | Carcinostatic substance tf-1323, its preparation, and carcinostatic agent containing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE8005921L SE8005921L (sv) | 1981-02-25 |
| SE446406B true SE446406B (sv) | 1986-09-08 |
Family
ID=27577343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8005921A SE446406B (sv) | 1979-08-24 | 1980-08-22 | Nya foreningar med karcinostatisk och immunostimulerande verkan framstellda genom odling av fusobacterium nucleatum tf-031(ferm 5077, atcc 31647), forfarande for framstellning av desamma och karcinostatiskt medel inneha |
Country Status (15)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2093347B (en) * | 1981-02-19 | 1985-03-27 | Toyama Chemical Co Ltd | Immunostimulant material tf-2 from fusobacterium sp |
| AU572529B2 (en) * | 1983-08-01 | 1988-05-12 | Furukawa, Keiichiro | Spf-100 and process for the preparation thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58318B2 (ja) * | 1977-07-11 | 1983-01-06 | 住友化学工業株式会社 | 制癌性物質の製造方法 |
-
1980
- 1980-08-18 DE DE19803031152 patent/DE3031152A1/de active Granted
- 1980-08-19 GB GB8027026A patent/GB2059969B/en not_active Expired
- 1980-08-20 CA CA000358667A patent/CA1174618A/en not_active Expired
- 1980-08-21 AU AU61646/80A patent/AU529076B2/en not_active Ceased
- 1980-08-21 AT AT0426480A patent/AT375674B/de active
- 1980-08-21 FI FI802641A patent/FI68080C/fi not_active IP Right Cessation
- 1980-08-21 CH CH6297/80A patent/CH648042A5/de not_active IP Right Cessation
- 1980-08-22 SE SE8005921A patent/SE446406B/sv not_active IP Right Cessation
- 1980-08-22 NO NO802499A patent/NO155697C/no unknown
- 1980-08-22 DK DK361680A patent/DK151639C/da not_active IP Right Cessation
- 1980-08-22 NZ NZ194744A patent/NZ194744A/en unknown
- 1980-08-22 PT PT71730A patent/PT71730A/pt unknown
- 1980-08-22 FR FR8018396A patent/FR2463619A1/fr active Granted
- 1980-08-22 IT IT49541/80A patent/IT1181595B/it active
- 1980-08-22 NL NL8004759A patent/NL8004759A/nl not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DK361680A (da) | 1981-02-25 |
| FR2463619A1 (fr) | 1981-02-27 |
| NO802499L (no) | 1981-02-25 |
| DE3031152C2 (enrdf_load_stackoverflow) | 1989-08-03 |
| AT375674B (de) | 1984-08-27 |
| PT71730A (en) | 1980-09-01 |
| DK151639B (da) | 1987-12-21 |
| IT8049541A0 (it) | 1980-08-22 |
| NO155697B (no) | 1987-02-02 |
| IT1181595B (it) | 1987-09-30 |
| FR2463619B1 (enrdf_load_stackoverflow) | 1984-11-30 |
| NZ194744A (en) | 1984-05-31 |
| FI68080B (fi) | 1985-03-29 |
| ATA426480A (de) | 1984-01-15 |
| CA1174618A (en) | 1984-09-18 |
| NL8004759A (nl) | 1981-02-26 |
| CH648042A5 (de) | 1985-02-28 |
| SE8005921L (sv) | 1981-02-25 |
| DK151639C (da) | 1988-06-20 |
| NO155697C (no) | 1987-05-13 |
| FI802641A7 (fi) | 1981-02-25 |
| DE3031152A1 (de) | 1981-03-19 |
| FI68080C (fi) | 1985-07-10 |
| GB2059969B (en) | 1983-05-18 |
| AU529076B2 (en) | 1983-05-26 |
| GB2059969A (en) | 1981-04-29 |
| AU6164680A (en) | 1981-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4043533B2 (ja) | 低分子量リポポリサッカライド | |
| Muramatsu et al. | Characterization of glycopeptides isolated from membranes of F9 embryonal carcinoma cells | |
| Volk | Quantitative assay of polysaccharide components obtained from cell wall lipopolysaccharides of Xanthomonas species | |
| Sentandreu et al. | Yeast cell-wall synthesis | |
| US20190002596A1 (en) | Sulfated heparin oligosaccharide and preparation method and application thereof | |
| Kaplan et al. | Studies on the turnover of plasma membranes in cultured mammalian cells.: II. Rates of synthesis and degradation of plasma membrane proteins and carbohydrates | |
| WO1990003791A1 (en) | Methods for interfering with hiv multiplication and composition for the treatment of aids | |
| Vos et al. | Distribution of acid mucopolysaccharides in subcellular fractions of mouse brain | |
| SE446406B (sv) | Nya foreningar med karcinostatisk och immunostimulerande verkan framstellda genom odling av fusobacterium nucleatum tf-031(ferm 5077, atcc 31647), forfarande for framstellning av desamma och karcinostatiskt medel inneha | |
| US4744985A (en) | Novel substances having carcinostatic and immunostimulating activity, process for preparing the same and carcinostatic agent containing the same | |
| Sisson | Stimulation of glucose utilization and glycosaminoglycans production by fibroblasts derived from retrobulbar tissue | |
| AU2020103108A4 (en) | Prawn head heparinoid, preparation method thereof, and use thereof in preparation of anticoagulant | |
| Rowson et al. | Size estimation by filtration of the enzyme-elevating virus of Riley | |
| US4547462A (en) | Process for preparing substance having carcinostatic and immunostimulating activity | |
| Huey et al. | Hyaluronic acid determinations: Optimizing assay parameters | |
| US3629235A (en) | Process for isolating an interferon inducer and the product per se | |
| EP0496351B1 (en) | Acid heteropolysaccharide, sulfated polysaccharide and process for producing the same | |
| CA1184864A (en) | Substances having carcinostatic and immunostimulating activity, process for preparing the same and carcinostatic agent containing the same | |
| Lloyd et al. | Regulation of the synthesis of mucin glycoproteins in swine trachea explants | |
| CN116675784A (zh) | 具有α-葡萄糖苷酶抑制作用的牡蛎糖胺聚糖及制备方法 | |
| del Rosso et al. | Selective exposure of mucopolysaccharides is involved in macrophage physiology | |
| US3718741A (en) | N-1 and N-2 FRACTIONS OF NEOCARZIONSTATIN | |
| Weinbaum et al. | Inhibition of envelope polymerizations in filamentous Escherichia coli B | |
| US3870698A (en) | Quintomycin compounds | |
| CN114230682A (zh) | 一种功能性香蕉多糖bpf2及其制备与应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NAL | Patent in force |
Ref document number: 8005921-5 Format of ref document f/p: F |
|
| NUG | Patent has lapsed |
Ref document number: 8005921-5 Format of ref document f/p: F |